<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCD</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-5329</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcd.2016.68031</article-id><article-id pub-id-type="publisher-id">WJCD-69899</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Surgery in the Acute Phase of Infective Endocarditis: 5 Years after Our Initial Experience
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Youssef</surname><given-names>El Bekkali</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Noureddine</surname><given-names>Atmani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Siham</surname><given-names>Bellouize</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Drissi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Younes</surname><given-names>Moutakiallah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mehdi</surname><given-names>Bamous</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdessamad</surname><given-names>Abdou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fouad</surname><given-names>Nya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anis</surname><given-names>Seghrouchni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahdi</surname><given-names>Aithoussa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Brahim</surname><given-names>Amahzoune</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdedaim</surname><given-names>Hatim Ghadbane</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdelatif</surname><given-names>Boulahya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Cardiac Surgery Department, Mohammed V Military Hospital, Rabat, Morocco</addr-line></aff><aff id="aff2"><addr-line>Reanimation of Cardiac Surgery Department, Mohamed V Medical Faculty, Rabat, Morocco</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>dratmani@hotmail.fr(NA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>08</month><year>2016</year></pub-date><volume>06</volume><issue>08</issue><fpage>275</fpage><lpage>284</lpage><history><date date-type="received"><day>26</day>	<month>May</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>16</month>	<year>August</year>	</date><date date-type="accepted"><day>19</day>	<month>August</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Aim: Comparing the results of acute phase infectious endocarditis surgery between two periods. Methods and Results: The study is about 2 series, series A between 1993 and 1997, and series B between 1998 and 2012, respectively 13 and 51 patients. The two periods were similar concerning the number of patients per year, which was 3.12 cases/year for series A and 3.64 cases/year for series B. The authors noted a change in epidemiological profile, with an increase of median age (31 y.o for series A and 37 y.o for series B), and the emergency of endocarditis on prosthetic valve (none on series A and 8 cases for series B). Surgical indications and results didn’t change too much, hospital mortality rate was 15.3% for series A and 17.6% for series B. Conclusion: Infectious endocarditis is still a major public healthcare problem in developing countries, despite the development of diagnostic tools and patient care. Prevention is still the major asset in the treatment of this disease.
 
</p></abstract><kwd-group><kwd>Infectious Endocarditis</kwd><kwd> Acute Phase</kwd><kwd> Surgery</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Valvular surgery performed during the active phase of infective endocarditis (IE) is indicated in an increasing</p><p>proportion of patients and currently ranges from 30% to 60%. Recent changes in the epidemiological and microbiological profile of the disease could explain this trend, with an increase in complicated situations due to a greater incidence of more virulent microorganisms and intracardiac material infections. Several works have determined the prognosis of patients who underwent surgery before the end of antimicrobial therapy; most showed that the advent of surgical therapy for complicated IE has been associated with reduced mortality. Thus, these results have encouraged physicians to offer surgical treatment for an increasing number of patients. Although the indications for surgery are well defined in international guidelines, no consensus exists on the optimal timing of surgical intervention because of a lack of evidence-based data. However, in patients with the most severe complications, surgery cannot be delayed and must be performed as soon as possible, frequently before the end of the first week of antimicrobial therapy. This very early surgical management, which can improve prognosis, raises the concern of the theoretical risk of both high operative mortality and recurrence or postoperative valve dysfunction (PVD) by implanting material into infected tissues. The aim of our work is to make a comparison between two periods of acute phase infective endocarditis surgery operated in the Department of Cardiovascular Surgery, Mohammed V Military Hospital, Rabat―Morocco.</p></sec><sec id="s2"><title>2. Materiel and Methods</title><p>This was a single center retrospective study conducted over two periods:</p><p>The first period runs from September 1993 to December 1997 [<xref ref-type="bibr" rid="scirp.69899-ref1">1</xref>] . (Series A) and 13 cases were included with an average of 3.12 patients/year, which reflected the initial experience of the department.</p><p>The second period runs from January 1998 to December 2012. (Series B) and 51 cases were included with an average of 3.64 patients/year.</p><p>Identification of patients was done from patients records, the diagnosis of infective endocarditis was established according to Duke criteria. All patients in this study group had surgery and were followed postoperatively for a period of 1 month. These medical records were reviewed to identify demographic, clinical, microbiological, operative and postoperative data.</p><p>All variables were entered to database using Microsoft excel and expressed as mean and/or percentage.</p></sec><sec id="s3"><title>3. Results</title><p>Although there is a difference between the number of patients and duration of both studies, the number of patients/year is substantially the same which allows us to make this comparison.</p><sec id="s3_1"><title>3.1. Distribution by Average Age (<xref ref-type="table" rid="table1">Table 1</xref>)</title><p>The average age of both series is respectively 31 and 37 y.o:</p><p> Series (A): 31 (9 - 42 y.o);</p><p> Series (B): 37 (9 - 60 y.o).</p></sec><sec id="s3_2"><title>3.2. Distribution by Sex (<xref ref-type="table" rid="table1">Table 1</xref>)</title><p>There were exclusively males in the first period, while in the second, the fifth of the patients were females.</p><p> Series (A): 100% Male;</p><p> Series (B): 78.4% Male and 21.6% Female.</p></sec><sec id="s3_3"><title>3.3. Initial Valvular Disease (on Clinical Findings and Echocardiogram) (<xref ref-type="table" rid="table1">Table 1</xref>)</title><p>In the first period, the valvular lesions were all rheumatic, while in the second period, we had some cases of prosthetic valvular endocarditis (8%).</p></sec><sec id="s3_4"><title>3.4. Preoperative Clinical State (<xref ref-type="table" rid="table1">Table 1</xref>)</title><p>More than three quarters of patients in both series were symptomatic (NYHA III, IV) with signs of left or global heart failure.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic and clinical characteristic</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Series A (n = 13)</th><th align="center" valign="middle" >Series B (n = 51)</th></tr></thead><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >31 (9 - 42)</td><td align="center" valign="middle" >37 (9 - 60)</td></tr><tr><td align="center" valign="middle" >Sex</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Male</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >78.4%</td></tr><tr><td align="center" valign="middle" >- Female</td><td align="center" valign="middle" >0%</td><td align="center" valign="middle" >21.6%</td></tr><tr><td align="center" valign="middle" >Etiology</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Rheumatic</td><td align="center" valign="middle" >(12) 92%</td><td align="center" valign="middle" >(43) 84%</td></tr><tr><td align="center" valign="middle" >- Bicuspid AV</td><td align="center" valign="middle" >(1) 8%</td><td align="center" valign="middle" >(4) 8%</td></tr><tr><td align="center" valign="middle" >- Prosthesis</td><td align="center" valign="middle" >0%</td><td align="center" valign="middle" >(4) 8%</td></tr><tr><td align="center" valign="middle" >Fever:</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >81.1%</td></tr><tr><td align="center" valign="middle" >NYHA:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Class I</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1 (5%)</td></tr><tr><td align="center" valign="middle" >- Class II</td><td align="center" valign="middle" >1 (7.6%)</td><td align="center" valign="middle" >15 (30%)</td></tr><tr><td align="center" valign="middle" >- Class III</td><td align="center" valign="middle" >8 (61.5%)</td><td align="center" valign="middle" >18 (36%)</td></tr><tr><td align="center" valign="middle" >- Class IV</td><td align="center" valign="middle" >4 (30.7%)</td><td align="center" valign="middle" >15 (30%)</td></tr><tr><td align="center" valign="middle" >Neurologic signs:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Ischemic Stroke</td><td align="center" valign="middle" >2 (15%)</td><td align="center" valign="middle" >4 (7.8%)</td></tr><tr><td align="center" valign="middle" >- Hemorrhagic stroke</td><td align="center" valign="middle" >0%</td><td align="center" valign="middle" >1 (1.9%)</td></tr><tr><td align="center" valign="middle" >ECG:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Sinus Rhythm</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >46</td></tr><tr><td align="center" valign="middle" >- Atrial Fibrillation</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >Chest radiograph: CTR</td><td align="center" valign="middle" >0.58 (0.55 - 0.70)</td><td align="center" valign="middle" >0.56 (0.55 - 0.68)</td></tr></tbody></table></table-wrap></sec><sec id="s3_5"><title>3.5. Echocardiographic Data</title><p>The echocardiographic findings are summarized in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>On both series, we noted a predominance of regurgitation lesions, but in the second series, there were some cases of prosthetic valvular endocarditis and on mitral valve alone.</p></sec><sec id="s3_6"><title>3.6. The Therapeutic Management (<xref ref-type="table" rid="table3">Table 3</xref>)</title><p>a) Antibiotics</p><p>All patients were under antibiotic treatment on admission including IV amoxicillin (200 mg/kg) and IV gentamicin (3 mg/kg) right after clinical suspicion. The treatment is then guided according to the clinical findings and the past medical history of each patient. The average duration of the preoperative antibiotic therapy was 23 days for the series A and 20 days for series B.</p><p>b) Bacteriologic Data</p><p>The alleged entry door was usually dental or ENT.</p><p>Blood cultures were in 46% of cases negative for series A and 66% negative for series B.</p><p>The bacterial agents found were mainly streptococcus and staphylococcus in series A, while in the series B we noticed the emergence of Klebsiella pneumoniae and Enterobacter cloacae.</p><p>c) Valve/Prosthesis Culture (<xref ref-type="table" rid="table3">Table 3</xref>)</p><p>In the Infective endocarditis with negative blood cultures, the culture of the valve or prosthesis isolated the</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Echocardiography data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Series A (n = 13)</th><th align="center" valign="middle" >Series B (n = 51)</th></tr></thead><tr><td align="center" valign="middle" >Vegetations</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Aortic</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >30</td></tr><tr><td align="center" valign="middle" >- Mitral</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >- Mitro-aortic</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >05</td></tr><tr><td align="center" valign="middle" >- Prosthesis</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >04</td></tr><tr><td align="center" valign="middle" >Ruptured Chord</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >05</td></tr><tr><td align="center" valign="middle" >Aortic annulus abscess</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >Valvular perforation</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >LV function</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- EF</td><td align="center" valign="middle" >56%</td><td align="center" valign="middle" >54%</td></tr><tr><td align="center" valign="middle" >- EF &lt; 40%</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >40%</td></tr><tr><td align="center" valign="middle" >- LVTDD</td><td align="center" valign="middle" >65 &#177; 7</td><td align="center" valign="middle" >63 &#177; 10</td></tr><tr><td align="center" valign="middle" >Site of lesions</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Aortic regurgitation (AR)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle" >- Mitral regurgitation (MR)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >- AR + MR</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >- AR + Mitral Disease</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >- AR + MR + TR</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >- Prosthesis</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >8</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> bacteriological data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Series A (n = 13)</th><th align="center" valign="middle" >Series B (n = 51)</th></tr></thead><tr><td align="center" valign="middle" >Mode of Entry</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Dental</td><td align="center" valign="middle" >06</td><td align="center" valign="middle" >04</td></tr><tr><td align="center" valign="middle" >- ENT</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >05</td></tr><tr><td align="center" valign="middle" >- Skin</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >03</td></tr><tr><td align="center" valign="middle" >- Pelvis</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >01</td></tr><tr><td align="center" valign="middle" >Blood cultures</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Positive</td><td align="center" valign="middle" >07</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle" >- Negative</td><td align="center" valign="middle" >06 (46%)</td><td align="center" valign="middle" >34 (66%)</td></tr><tr><td align="center" valign="middle" >Bacteria</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Streptococcus</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >08</td></tr><tr><td align="center" valign="middle" >- Staphylococcus</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >07</td></tr><tr><td align="center" valign="middle" >- Enterobacter cloacae</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >01</td></tr><tr><td align="center" valign="middle" >- Klebsiella pneumoniae</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >01</td></tr><tr><td align="center" valign="middle" >Positive valve culture</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >- Streptococcus</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >- Staphylococcus</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Positive prosthesis culture</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >- Staphylococcus</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >- Enterobacter</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>responsible bacteria in 2 cases (6.33%) of the first series, and in 6 cases (34%) of the second one.</p><p>d) Heart Failure Treatment</p><p>The symptomatic post operative treatment of heart failure was prescribed for 8 patients (61.5%) for the series A and 31 patients for the series B (60.7%).</p><p>e) Surgical Treatment (<xref ref-type="table" rid="table4">Table 4</xref>)</p><p>The surgery was performed by median sternotomy, cardiopulmonary bypass was installed. Myocardial protection was performed by moderated hypothermia and cold cardioplegic solution.</p><p>Closing annular abscess: in fact the patient was having annular cover spontaneously evacuated, and it was sutured by single patched stitches before the introduction of the prosthesis.</p><p>Hospital mortality (1 month) was 15.3% (2/13) for Series A and 17% (9/51) for series B. The causes of death are summarized in <xref ref-type="table" rid="table5">Table 5</xref>.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Operative data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Series A</th><th align="center" valign="middle" >Series B</th></tr></thead><tr><td align="center" valign="middle" >Indications</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Haemodynamic reasons</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >31</td></tr><tr><td align="center" valign="middle" >- High emboli risk</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >- Uncontrolled infectious syndrome</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Surgical interventions</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- MVR</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >- AVR</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >- AVR+MVR</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >16</td></tr><tr><td align="center" valign="middle" >- Prosthesis change</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >- Tricuspid valve Repair</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >- Annular abcess closure</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >CPB Average time (min)</td><td align="center" valign="middle" >100 (40 - 180)</td><td align="center" valign="middle" >108 (35 - 200)</td></tr><tr><td align="center" valign="middle" >Aortic clumping time (min)</td><td align="center" valign="middle" >69 (45 - 140)</td><td align="center" valign="middle" >74 (50 - 150)</td></tr><tr><td align="center" valign="middle" >Vasoactive drugs</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >38</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Mortality and morbidity</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Series A (n = 13)</th><th align="center" valign="middle" >Series B (n = 51)</th></tr></thead><tr><td align="center" valign="middle" >Hospital mortality</td><td align="center" valign="middle" >15.3%</td><td align="center" valign="middle" >17%</td></tr><tr><td align="center" valign="middle" >Average ICU time (days)</td><td align="center" valign="middle" >02 (1 - 10)</td><td align="center" valign="middle" >03 (1 - 17)</td></tr><tr><td align="center" valign="middle" >Low Flow</td><td align="center" valign="middle" >06 (46%)</td><td align="center" valign="middle" >16 (31%)</td></tr><tr><td align="center" valign="middle" >Arrythmia</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle" >Conduction disorder</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >04</td></tr><tr><td align="center" valign="middle" >Lung Disease</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >03</td></tr><tr><td align="center" valign="middle" >Post operative bleeding (ml)</td><td align="center" valign="middle" >550 (200 - 1500)</td><td align="center" valign="middle" >610 (200 - 1800)</td></tr><tr><td align="center" valign="middle" >Transfusion</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >Cardiogenic shock</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >04</td></tr><tr><td align="center" valign="middle" >Septic shock</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >02</td></tr><tr><td align="center" valign="middle" >Tamponnade</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01</td></tr><tr><td align="center" valign="middle" >Prosthesis disinsertion</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >02</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4"><title>4. Discussion</title><p>Long ago, the epidemiological profile of infective endocarditis in undeveloped countries like Morocco, was characterized by the young age, the incidence of rheumatic lesions favoring bacterial transplantation and the prevalence of Streptococcus.</p><p>But comparing the two series has enabled us to identify three epidemiological changes.</p><p> The average age has increased by 5 years, from 32 y.o to 37 y.o, which is due to the improving of life expectancy in Morocco, that rose from 69 y.o in 2000 to 76 y.o in 2012. But it remains largely lower than what’s known in reviews [<xref ref-type="bibr" rid="scirp.69899-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref3">3</xref>] and this is explained by the remaining of rheumatic lesions in our country mainly affecting young adults.</p><p> We also noticed the female’s appearence in the second series with a proportion of 21% which is lower than what’s known in reviews 30% [<xref ref-type="bibr" rid="scirp.69899-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref3">3</xref>] the predominance of male patients in both series is due to our patient’s recruitment which is predominantly military.</p><p> The incidence of rheumatic valvular heart disease remains largely dominant but we noted the emergence of prosthetic valve endocarditis with a proportion of 8% lower than reviews (21%) [<xref ref-type="bibr" rid="scirp.69899-ref4">4</xref>] , probably also because of our recruitment in a specific population (military), on the other hand our practice has started in 1993, before that, the patients were operated in France.</p><p>But these series are still totally different from what is currently observed in Europe or the USA. In these countries the age of onset is late and rheumatic endocarditis lesions have almost disappeared, the main cause in these countries is degenerative lesions and valvular prosthesis [<xref ref-type="bibr" rid="scirp.69899-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref3">3</xref>] .</p><p>Clinically we noted two points:</p><p> The Appearance of IE on native mitral valve isolated with a proportion of 12% which is still lower than the data in the Reviews which is around 26% [<xref ref-type="bibr" rid="scirp.69899-ref5">5</xref>] this is due to the fact that our series is exclusively surgical.</p><p> The very high incidence of heart failure noted in both series. All patients have valvular lesions or prosthesis, with fever and more than 3/4 of the patients were symptomatic (II, III, IV NYHA) which suggests the diagnosis (based on clinical findings, blood cultures and echocardiography).</p><p>The association of new onset heart failure with fever must make the diagnosis of IE highly probable [<xref ref-type="bibr" rid="scirp.69899-ref6">6</xref>] . Heart failure usually occurs more frequently in aortic lesions (29%) than mitral (20%) or tricuspid (8%) [<xref ref-type="bibr" rid="scirp.69899-ref7">7</xref>] , and may happen acutely (by perforation) or insidiously (consequence of old valvular lesions decompensated by EI) and that is the case for the majority of our patients as evidenced by symptoms and cardiomegaly on chest radiograph with the average CTR &gt; 0.55 and LV dilation on echocardiography &gt; 64 mm on both series.</p><p>Neurological complications are second to heart failure and occur in 30% to 40% of cases. This is due to vegetation’s migration causing an ischemic stroke, or hemorrhagic stroke by the convertion of a white infarction, or mycotic aneurysm rupture [<xref ref-type="bibr" rid="scirp.69899-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref9">9</xref>] . The percentage of strokes was 15% for A series and 9.8% for B series, which is still very low compared with reviews, probably due to that the two series are purely surgical.</p><p>The diagnosis of IE is clinically suspected in the presence of a fever and cardiovascular examination findings (regurgitation heart murmur) and confirmed by echocardiographic examination showing evocative pictures (vegetation, abscess).</p><p>Concerning native valve vegetation, transthoracic echocardiogram had a sensitivity rate of 0.8 and this rate reaches 0.92 in Transoesophageal echocardiogram [<xref ref-type="bibr" rid="scirp.69899-ref10">10</xref>] . Yet the diagnosis remains unclear if there are calcifications or prosthesis [<xref ref-type="bibr" rid="scirp.69899-ref11">11</xref>] . It is commonly known that large vegetations (more than 1 cm) [<xref ref-type="bibr" rid="scirp.69899-ref12">12</xref>] .</p><p>The comparison of echocardiographic data allowed us to note that aortic disease is the most frequent followed by mitro-aortic lesions and then mitral prosthesis, contrary to reviews in which we note the predominance of aortic lesions, then mitral, prosthesis, and mitroaortic at last [<xref ref-type="bibr" rid="scirp.69899-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref13">13</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref15">15</xref>] , this is because the underlying disease for the majority of our patients is rheumatic disease, often multivalvular.</p><p>Bacteriologically, we unfortunately noted a very high percentage of negative blood cultures (46%) for Series A and (66%) for Series B compared with the data of Western reviews that doesn’t exceed 10% [<xref ref-type="bibr" rid="scirp.69899-ref5">5</xref>] but is close to the North African reviews (47.3%) [<xref ref-type="bibr" rid="scirp.69899-ref16">16</xref>] . This can be explained by the systematic prescription of antibiotics to treat a fever or insufficient laboratories.</p><p>Indeed, in case of a negative blood culture the following possibilities should be discussed.</p><p>→ The conditions of the blood samples: time, number, and volume components of critical conditions;</p><p>→ Prior antibiotics;</p><p>→ Endocarditis related germs.</p><p> Slow growth requiring prolonged group culture HAECK</p><p> intracellular development coxiella, bartonella…</p><p> Yeast</p><p>Removed valves/prosthesis culture allowed a mild raise of the number of germs which were identified by positive blood culture, dominated by streptococci and staphylococci which joins the data in the reviews [<xref ref-type="bibr" rid="scirp.69899-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref17">17</xref>] . But we also noted Enterobacteria in the B series.</p><p>Since the 80s the development of cardiac surgery and the progress in medical investigations has contributed to the reduction of IE mortality when is operated in the active phase, and to identify its indications. Indeed, these data are hemodynamic status, biological and Embolic disorders [<xref ref-type="bibr" rid="scirp.69899-ref18">18</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref20">20</xref>] .</p><p>Early surgery in the active phase avoids progressive heart failure, irreversible structural damage and systemic embolism [<xref ref-type="bibr" rid="scirp.69899-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref22">22</xref>] . The most dangerous complication otherwise is a persistent or recurrent endocarditis which is not influenced by the duration of pre-operative antibiotics treatment [<xref ref-type="bibr" rid="scirp.69899-ref23">23</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref25">25</xref>] on the one hand and on the other hand the risk is controversial, important for some [<xref ref-type="bibr" rid="scirp.69899-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref27">27</xref>] and significant for others [<xref ref-type="bibr" rid="scirp.69899-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref29">29</xref>] .</p><p>Comparing the surgical indications in both series, we found that the hemodynamic indications were exclusive to the A Series and largely dominant in the B series that joins data from the reviews. But we especially noted the appearance in the B series of other indications such as embolic risk and uncontrolled infection.</p><p>Heart failure was the main operative indication in the active phase since the mortality of IE on native valve in case of heart failure is 55% - 80% without surgery, decreasing to 10% - 35% with surgery. But this rate is dependent on two factors: Dyspnea stage and the time between the installation of the heart failure and surgery, the less the period is, better are the results [<xref ref-type="bibr" rid="scirp.69899-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref31">31</xref>] .</p><p>The embolic risk increased especially in case of vegetation with a diameter &gt; 10 mm or highly mobile [<xref ref-type="bibr" rid="scirp.69899-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref32">32</xref>] or related to certain microorganisms (Staphylococcus, Streptococcus bovis, candida). This indication usually occupies the 3rd place in the surgical indication chart in the active phase, and is in the 2nd place in our series 27% which is due to the fact that the majority of our patients have polyvalvular lesions.</p><p>The none-control of the infection is usually the second indication, we noted it in 4% of our patients, in which we count the persistent infection, 7 to 10 days of antibiotics or due to infection by resistant microorganisms. It must be done as quickly as possible because there is a high risk of fistulas, abscesses and pseudo aneurysm [<xref ref-type="bibr" rid="scirp.69899-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref33">33</xref>] .</p><p>The problem for the surgical indication in case of a stroke should be discussed case by case. It seems that if the risk of hemorrhagic transformation is reliable to 20% if the patient is operated before 72 hours, the risk increases to 50% between 4 and 14 days, then it returns to nearly zero after the 4th week. But the risks of worsening are considerable in the first four weeks in case of cerebral bleeding [<xref ref-type="bibr" rid="scirp.69899-ref34">34</xref>] . Thus the period of at least 3 - 4 weeks should elapse before surgery if the patient’s condition is stable.</p><p>The main goal of surgery for infective endocarditis is to eradicate infected tissues and to restore the valvular structure either by valve repair (especially for mitral or tricuspid), homograft or prosthesis [<xref ref-type="bibr" rid="scirp.69899-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref36">36</xref>] .</p><p>In both series no cases of mitral valve repair could be made, given the importance of rheumatic alterations of the valve. Due to the young age of our patients we chose mechanical valve replacement. As for homograft valves are not yet used in our country.</p><p>The mortality rate in the two series is essentially the same (15.3%, 17%) which is comparable to a Tunisian series (13%) [<xref ref-type="bibr" rid="scirp.69899-ref16">16</xref>] . Tunisia is a country like ours with the same epidemiological characteristics. But seems higher compared to that of Western series [<xref ref-type="bibr" rid="scirp.69899-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref38">38</xref>] , this is due to the fact that the majority of our patients were at an advanced stage of their valvular disease as evidenced by their functional status (more than 70% in stage III, NYHA IV).</p><p>It is proven that the prognosis of IE operated at a stage II NYHA dyspnea is more favorable than stage III, IV [<xref ref-type="bibr" rid="scirp.69899-ref37">37</xref>] - [<xref ref-type="bibr" rid="scirp.69899-ref39">39</xref>] . This highlights the importance of surveillance and prophylaxis of patients with valvular prosthesis to avoid an endocarditis darkening the prognosis.</p><p>Currently, the long term prognosis of operated EI patients is good with a mortality rate 36% patient-years [<xref ref-type="bibr" rid="scirp.69899-ref40">40</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref41">41</xref>] and 5-year survival is up to 60% to 90% depending on type of endocarditis, on native or prosthetic valve type, and surgery (repair or replacement) [<xref ref-type="bibr" rid="scirp.69899-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.69899-ref43">43</xref>] .</p><p>Despite the retrospective nature of the study and small number of patients included, this study permitted us to better understand the management of these patients with this condition.</p></sec><sec id="s5"><title>5. Conclusions</title><p>10 years since the publication of our very first series on infectious endocarditis, the disease is still relevant whether on native or prosthetic valve. It is characterized in our country on the one hand by the young age of onset and on the other, by the predominance of rheumatic lesions often advanced, precipitating the worsening of the hemodynamic status.</p><p>This context makes the indication for surgery in the active phase often legitimate before the onset of myocardial degeneration.</p><p>But despite the very encouraging progress in surgery, prophylactic measures should not, however, be overshadowed.</p></sec><sec id="s6"><title>Cite this paper</title><p>Youssef El Bekkali,Noureddine Atmani,Siham Bellouize,Mohamed Drissi,Younes Moutakiallah,Mehdi Bamous,Abdessamad Abdou,Fouad Nya,Anis Seghrouchni,Mahdi Aithoussa,Brahim Amahzoune,Abdedaim Hatim Ghadbane,Abdelatif Boulahya, (2016) Surgery in the Acute Phase of Infective Endocarditis: 5 Years after Our Initial Experience. World Journal of Cardiovascular Diseases,06,275-284. doi: 10.4236/wjcd.2016.68031</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.69899-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">el Bekkali, Y., Boulahya, A., Wahid, F., Aouifi, A., Amehzoune, B., Salkane, C., Arji, M. and el Kirat, M. (2001) Surgery of Active-Phase Infective Endocarditis: Report of 13 Cases. Annales de Cardiologie et d’Angéiologie (Paris), 50, 269-273. http://dx.doi.org/10.1016/S0003-3928(01)00031-2</mixed-citation></ref><ref id="scirp.69899-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Delahaye, F., Goulet, V., Lacassin, F., Ecochard, R., Selton-Suty, C., Hoen, B., et al. (1995) Characteristics of Infective Endocarditis in France in 1991. A 1-Year Survey. European Heart Journal, 16, 394-401.</mixed-citation></ref><ref id="scirp.69899-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Goulet, V., Etienne, J., Fleurette, J. and Netter, R. (1986) Caracteristiques epidemiologiques de l'endocardite infectieuse en France. La Presse Médicale, 14, 1855-1858.</mixed-citation></ref><ref id="scirp.69899-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Selton-Suty, C., Iung, B., Bernard, Y., Donal, E., Nazerollas, P., Sportouch-Dukhan, C., et al. (2010) Continuing Changing Profile of Infective Endocarditis: Results of a Repeat One-Year Population-Based Survey in France in 2008. European Heart Journal, 31, 467.</mixed-citation></ref><ref id="scirp.69899-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Delahaye, J.P., Loire, R., Delahaye, F. and Vandenesch, H.B. (2000) Endocardites infectieuses. Encycl Méd Chir. Cardiologie, 11-013-B-10, 25 p.</mixed-citation></ref><ref id="scirp.69899-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">McKinsey, D.S., Ratts, T.E. and Bisno, A.L. (1987) Underlying Cardiac Lesions in Adults with Infective Endocarditis. The Changing Spectrum. The American Journal of Medicine, 82, 681-688. http://dx.doi.org/10.1016/0002-9343(87)90001-5</mixed-citation></ref><ref id="scirp.69899-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Baddour, L.M., Wilson, W.R., Bayer, A.S., Fowler Jr., V.G., Bolger, A.F., Levison, M.E., et al. (2005) Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation, 111, e394-e434. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.165564</mixed-citation></ref><ref id="scirp.69899-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Thuny, F., Avierinos, J.-F., Tribouilloy, C., Giorgi, R., Casalta, J.-P., Milandre, L., et al. (2007) Impact of Cerebrovascular Complications on Mortality and Neurologic Outcome during Infective Endocarditis: A Prospective Multicentre Study. European Heart Journal, 28, 1155-1161. http://dx.doi.org/10.1093/eurheartj/ehm005</mixed-citation></ref><ref id="scirp.69899-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cabell, C.H., Pond, K.K., Peterson, G.E., Durack, D.T., Corey, G.R., Anderson, D.J., et al. (2001) The Risk of Stroke and Death in Patients with Aortic and Mitral Valve Endocarditis. American Heart Journal, 142, 75-80. http://dx.doi.org/10.1067/mhj.2001.115790</mixed-citation></ref><ref id="scirp.69899-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jacob, S. and Tong, A. (2002) Role of Echocardiography in the Diagnosis and Management of Infective Endocarditis. Current Opinion in Cardiology, 17, 478-485. http://dx.doi.org/10.1097/00001573-200209000-00006</mixed-citation></ref><ref id="scirp.69899-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Habib, G. (2003) Apport de l’échographie dans l’endocardite infectieuse. Archive des maladies du coeur et des vaisseaux. Tome 96 spécial V, Juin 2003.</mixed-citation></ref><ref id="scirp.69899-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Thuny, F., Di Salvo, G., Belliard, O., Avierinos, J.F., Pergola, V., Rosenberg, V., et al. (2005) Risk of Embolism and Death in Infective Endocarditis: Prognostic Value of Echocardiography: A Prospective Multicenter Study. Circulation, 112, 69-75. http://dx.doi.org/10.1161/CIRCULATIONAHA.104.493155</mixed-citation></ref><ref id="scirp.69899-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Karalis, D.G., Bansal, R.C., Hauck, A.J., Ross Jr., J.J., Applegate, P.M. and Jutzy, K.R. (1992) Transesophageal Echocardiographic Recognition of Subaortic Complications in Aortic Valve Endocarditis. Clinical and Surgical Implications. Circulation, 86, 353-362. http://dx.doi.org/10.1161/01.CIR.86.2.353</mixed-citation></ref><ref id="scirp.69899-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tleyjeh, I.M., Abdel-Latif, A., Rahbi, H., Scott, C.G., Bailey, K.R., Steckelberg, J.M., et al. (2007) A Systematic Review of Population-Based Studies of Infective Endocarditis. Chest, 132, 1025-1035. http://dx.doi.org/10.1378/chest.06-2048</mixed-citation></ref><ref id="scirp.69899-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Horscotte, D. (1991) Prosthetic Valve Endocarditis. IRCC Publichers, London, 229-261.</mixed-citation></ref><ref id="scirp.69899-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tarmiz, A., Jebri, S., et al. (2010) Chirurgie de l’endocardite sur valves natives à la phase active. Annales de Cardilogie et d’Angéiologie, 59, 8-13.</mixed-citation></ref><ref id="scirp.69899-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Van der Meer, J.T., van Vianen, W., Hu, E., van Leeuwen, W.B., Valkenburg, H.A., Thompson, J. and Michel, M.F. (1991) Distribution, Antibiotic Susceptibility and Tolerance of Bacterial Isolates in Culture-Positive Cases of Endocarditis in The Netherlands. European Journal of Clinical Microbiology and Infectious Diseases, 10, 728-734. http://dx.doi.org/10.1007/BF01972497</mixed-citation></ref><ref id="scirp.69899-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tornos, P., Iung, B., Permanyer-Miralda, G., Baron, G., Delahaye, F., Gohlke-Barwolf, Ch., et al. (2005) Infective Endocarditis in Europe: Lessons from the Euro Heart Survey. Heart, 91, 571-575. http://dx.doi.org/10.1136/hrt.2003.032128</mixed-citation></ref><ref id="scirp.69899-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Olaison, L. and Pettersson, G. (2003) Current Best Practices and Guidelines. Indications for Surgical Intervention in Infective Endocarditis. Cardiology Clinics, 21, 235-251. http://dx.doi.org/10.1016/S0733-8651(03)00029-8</mixed-citation></ref><ref id="scirp.69899-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">(2005) Recommandations de la Société francaise de cardiologie concernant la prise en charge des valvulopathies acquises et des dysfonctions de prothèse valvulaire. Archives des Maladies du Caeur et des Vaisseaux, 98.</mixed-citation></ref><ref id="scirp.69899-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hasbun, R., Vikram, H.R., Barakat, L.A., Buenconsejo, J. and Quagliarello, V.J. (2003) Complicated Left Sided Native Valve Endocarditis in Adults: Risk Classification for Mortality. JAMA, 289, 1933-1940. http://dx.doi.org/10.1001/jama.289.15.1933</mixed-citation></ref><ref id="scirp.69899-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Aksoy, O., Sexton, D.J., Wang, A., Pappas, P.A., Kourany, W., Chu, V., et al. (2007) Early Surgery in Patients with Infective Endocarditis: A Propensity Score Analysis. Clinical Infectious Diseases, 44, 364-372. http://dx.doi.org/10.1086/510583</mixed-citation></ref><ref id="scirp.69899-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Agnihotri, A.K., McGiffin, D.C., Galbraith, A.J. and O’Brien, M.F. (1995) The Prevalence of Infective Endocarditis after Aortic Valve Replacement. The Journal of Thoracic and Cardiovascular Surgery, 110, 1708-1720.</mixed-citation></ref><ref id="scirp.69899-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Olaison, L., Hogevik, H., Myken, P., Oden, A. and Alestig, K. (1996) Early Surgery in Infective Endocarditis. QJM, 89, 267-278. http://dx.doi.org/10.1093/qjmed/89.4.267</mixed-citation></ref><ref id="scirp.69899-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">D’Udekem, Y., David, T.E., Feindel, C.M., Armstrong, S. and Sun, Z. (1997) Long-Term Results of Surgery for Active Infective Endocarditis. European Journal Cardio-Thoracic Surgery, 11, 46-52. http://dx.doi.org/10.1016/S1010-7940(96)01020-2</mixed-citation></ref><ref id="scirp.69899-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chastre, J. and Trouillet, J.L. (1995) Early Infective Endocarditis on Prosthetic Valves. European Heart Journal, 16, 32-38. http://dx.doi.org/10.1093/eurheartj/16.suppl_B.32</mixed-citation></ref><ref id="scirp.69899-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, M., Witchitz, S., Chastang, C., Régnier, B. and Vachon, F. (1995) Prosthetic Valve Endocarditis in the ICU. Prognostic Factors of Overall Survival in a Series of 122 Cases and Consequences for Treatment Decision. Chest, 108, 688-694. http://dx.doi.org/10.1378/chest.108.3.688</mixed-citation></ref><ref id="scirp.69899-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Aranki, S.F., Adams, D.H., Rizzo, R.J., Couper, G.S., Sullivan, T.E., Collins Jr., J.J. and Cohn, L.H. (1995) Determinants of Early Mortality and Late Survival in Mitral Valve Endocarditis. Circulation, 92, 143-149. http://dx.doi.org/10.1161/01.CIR.92.9.143</mixed-citation></ref><ref id="scirp.69899-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Verheul, H.A., van den Brink, R.B., van Vreeland, T., Moulijn, A.C., Düren, D.R. and Dunning, A.J. (1993) Effects of Changes in Management of Active Infective Endocarditis on Outcome in a 25-Year Period. The American Journal of Cardiology, 72, 682-687. http://dx.doi.org/10.1016/0002-9149(93)90885-G</mixed-citation></ref><ref id="scirp.69899-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Delahaye, J.P., Malquarti, V., Sara Darian, W., et al. (1987) Pronostic de l’endocardite infectieuse opérée. Archives des Maladies du Coeur et des Vaisseaux, 80, 302-309.</mixed-citation></ref><ref id="scirp.69899-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Witchitz, S., Reidiboym, M., Bouvet, E., Wolff, M. and Vachon, F. (1986) Evolution des facteurs pronostiques de l’endocardite infectieuse sur une période de 16 ans à propos de 471 observations. Archives des Maladies du Coeur et des Vaisseaux, 85, 959-965.</mixed-citation></ref><ref id="scirp.69899-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dickerman, S.A., Abrutyn, E., Barsic, B., Bouza, E., Cecchi, E., Moreno, A., et al. (2007) The Relationship between the Initiation of Antimicrobial Therapy and the Incidence of Stroke in Infective Endocarditis: An Analysis from the ICE Prospective Cohort Study (ICE-PCS). American Heart Journal, 154, 1086-1094. http://dx.doi.org/10.1016/j.ahj.2007.07.023</mixed-citation></ref><ref id="scirp.69899-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Prendergast, B.D. (2006) The Changing Face of Infective Endocarditis. Heart, 92, 879-885. http://dx.doi.org/10.1136/hrt.2005.067256</mixed-citation></ref><ref id="scirp.69899-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Angstwurm, K., Borges, A.C., Halle, E., Schielke, E., Einhaupl, K.M. and Weber, J.R. (2004) Timing the Valve Replacement in Infective Endocarditis Involving the Brain. Journal of Neurology, 251, 1220-1226. http://dx.doi.org/10.1007/s00415-004-0517-x</mixed-citation></ref><ref id="scirp.69899-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Acar, C. (2007) Early Surgery in Mitral Valve Endocarditis: It Is Sometimes Too Early. European Journal Cardio-Thoracic Surgery, 32, 947.http://dx.doi.org/10.1016/j.ejcts.2007.08.020</mixed-citation></ref><ref id="scirp.69899-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Kerchove, L., Vanoverschelde, J.L., Poncelet, A., Glineur, D., Rubay, J., Zech, F., Noirhomme, P. and El Khoury, G. (2007) Reconstructive Surgery in Active Mitral Valve Endocarditis: Feasibility, Safety and Durability. European Journal Cardio-Thoracic Surgery, 31, 592-599. http://dx.doi.org/10.1016/j.ejcts.2007.01.002</mixed-citation></ref><ref id="scirp.69899-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Thuny, F., Beurtheret, S., Gariboldi, V., Mancini, J., Avierinos, J.F., Riberi, A., et al. (2008) Outcome after Surgical Treatment Performed within the First Week of Antimicrobial Therapy during Infective Endocarditis: A Prospective Study. Archives of Cardiovascular Diseases, 101, 687-695.</mixed-citation></ref><ref id="scirp.69899-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Delay, D., Pellerin, M., Carrier, M., Marchand, R., Auger, P., Perrault, L.P., Hébert, Y., Cartier, R., Pagé, P. and Pelletier, L.C. (2000) Immediate and Long Term Results of Valve Replacement for Native and Prosthetic Valve Endocarditis. The Annals of Thoracic Surgery, 70, 1219-1223. http://dx.doi.org/10.1016/S0003-4975(00)01887-7</mixed-citation></ref><ref id="scirp.69899-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Iung, B., Rousseau-Paziaud, J., Cormier, B., Garbarz, E., Fondard, O., Brochet, E., Acar, C., et al. (2004) Contemporary Results of Mitral Valve Repair for Infective Endocarditis. Journal of the American College of Cardiology, 43, 386-392. http://dx.doi.org/10.1016/j.jacc.2003.09.034</mixed-citation></ref><ref id="scirp.69899-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Young, J.B., Welton, D.E., Raizner, A.E., et al. (1979) Surgery in Active Endocarditis. Circulation, 60, 177-181. http://dx.doi.org/10.1161/01.CIR.60.2.77</mixed-citation></ref><ref id="scirp.69899-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Castillo, J.C., Anguita, M.P., Ramírez, A., Siles, J.R., Torres, F., Mesa, D., et al. (2000) Long Term Outcome of Infective Endocarditis in Patients Who Were Not Drug Addicts: A 10 Year Study. Heart, 83, 525-530. http://dx.doi.org/10.1136/heart.83.5.525</mixed-citation></ref><ref id="scirp.69899-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Michel, P.L., Lung, B., Drissi, F., Dadez, E., Cormier, B., Acar, C., et al. (1994) La chirurgie mitrale conservatrice dans le traitement de l’insuffisance mitrale infectieuse. Archives des Maladies du Coeur et des Vaisseaux, 87, 349-355.</mixed-citation></ref><ref id="scirp.69899-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Mullany, C.J., Chua, Y.L., Schaff, H.V., Steckelberg, J.M., Ilstrup, D.M., Orszulak, T.A., et al. (1995) Early and Late Survival after Surgical Treatment of Culture Positive Active Endocarditis. Mayo Clinic Proceedings, 70, 517-525. http://dx.doi.org/10.4065/70.6.517</mixed-citation></ref></ref-list></back></article>